Last €2.93 EUR
Change Today -0.035 / -1.18%
Volume 0.0
EZB On Other Exchanges
New York
As of 2:15 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

enzo biochem inc (EZB) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/14 - €4.66
52 Week Low
01/30/14 - €1.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENZO BIOCHEM INC (EZB)

enzo biochem inc (EZB) Related Businessweek News

No Related Businessweek News Found

enzo biochem inc (EZB) Details

Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 35 patient service centers in New York and New Jersey; and a standalone laboratory in the New York, as well as a full-service phlebotomy, in-house logistics department, and information technology department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

433 Employees
Last Reported Date: 10/9/14
Founded in 1976

enzo biochem inc (EZB) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $555.5K
Co-Founder, President, Chief Financial Office...
Total Annual Compensation: $492.7K
Senior Vice President of Finance
Total Annual Compensation: $123.8K
Vice President of Corporate Development
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2014.

enzo biochem inc (EZB) Key Developments

Enzo Biochem Inc. Announces Executive Changes

Enzo Biochem Inc. held its Annual Meeting of Shareholders on January 21, 2015. The company elected Elazar Rabbani as a Class III Director on the Board of Directors to hold office for a term of three years or until his successor.

Enzo Biochem Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Enzo Biochem Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Enzo Biochem Inc. Reports Unaudited Earnings Results for the First Quarter Ended October 31, 2014

Enzo Biochem Inc. reported unaudited earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported total revenues of $24,824,000 compared to $24,134,000 reported a year ago. Loss before income taxes was $3,606,000 compared to $2,724,000 reported a year ago. Net loss was $3,729,000 or $0.08 per basic and diluted share compared to $2,787,000 or $0.07 per basic and diluted share reported a year ago. Non-GAAP net loss was $3,729,000 or $0.08 per basic and diluted share compared to $2,787,000 or $0.07 per basic and diluted share reported a year ago. LBITDA and adjusted LBITDA was $2,599,000 compared to $1,637,000 reported a year ago. Total operating loss unchanged from a year ago, despite higher legal expenses as expected given patent cases being heard and moving through discovery phase. The improved fiscal first quarter results reflected the transformative program it instituted to enhance operations. Cash flow used in operations during the quarter was $2.8 million. This is lower by $500,000 than the prior year period.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EZB:GR €2.93 EUR -0.035

EZB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NanoString Technologies Inc $12.52 USD -0.34
NeoGenomics Inc $3.92 USD -0.01
Psychemedics Corp $14.80 USD +0.05
Response Genetics Inc $0.45 USD +0.068
WaferGen Bio-systems Inc $3.13 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation EZB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZO BIOCHEM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at